Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

• Main Authors: Lijing Jiao (Author), Jianfang Xu (Author), Jianli Sun (Author), Zhiwei Chen (Author), Yabin Gong (Author), Ling Bi (Author), Yan Lu (Author), Jialin Yao (Author), Weirong Zhu (Author), Aihua Hou (Author), Gaohua Feng (Author), Yingjie Jia (Author), Weisheng Shen (Author), Yongjian Li (Author), Ziwen Zhang (Author), Peiqi Chen (Author), Ling Xu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: To determine the clinical activity and safety of Chinese herbal medicine (CHM) combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in patients with advanced pulmonary adenocarcinoma (ADC) and the ability of CHM combined with EGFR-TKI to activate EGFR muta...